Earnings call Suven and Cohance reported a 4.1% YoY revenue decline on a combined basis in Q2 FY25, with Suven's pharma CDMO growing 40% YoY while Cohance saw a 13% YoY decline due to shipment phasing ...

Feb 20, 2026, 4:30 PM IST Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Feb 16, 2026, 10:17 PM IST Cohance Lifesciences - Announcement under ...

Jefferies sets ₹1,150 target price indicating 30% upside Specialty chemicals sales fell but expected to recover by FY26 Pharma CDMO destocking likely to resolve within two quarters Shares of Cohance ...

Shares of Cohance Lifesciences Ltd slipped 10% on Wednesday after the company said V Prasada Raju has resigned from the position of Managing Director and Director with immediate effect on October 28.

The sell-off in Cohance Lifesciences deepened further in Friday's trading session, with the stock crashing another 2.2% to ₹615 apiece, the lowest level since June 2024. This extended its losing ...

Cohance Lifesciences, a leading integrated contract development and manufacturing organization (CDMO), has appointed Yann D’Herve as chief executive officer of the company’s CDMO business. The ...

Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) will hold its 7th Annual General Meeting (AGM) on Friday, September 19, 2025, at 2:30 p.m. (IST). The meeting will be conducted ...

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in ...